Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial

Rationale: Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke. Importantly, the risk of recurrence is highest immediately after the index event while antiplatelets cause bleeding. Aims and/or hypothesis: The ‘Triple Anti...

Full description

Bibliographic Details
Main Authors: Bath, Philip M.W., Robson, Katie, Woodhouse, Lisa J., Sprigg, Nikola, Dineen, Robert A., Pocock, Stuart J.
Format: Article
Published: SAGE Publications 2015
Online Access:https://eprints.nottingham.ac.uk/35717/
_version_ 1848795145281994752
author Bath, Philip M.W.
Robson, Katie
Woodhouse, Lisa J.
Sprigg, Nikola
Dineen, Robert A.
Pocock, Stuart J.
author_facet Bath, Philip M.W.
Robson, Katie
Woodhouse, Lisa J.
Sprigg, Nikola
Dineen, Robert A.
Pocock, Stuart J.
author_sort Bath, Philip M.W.
building Nottingham Research Data Repository
collection Online Access
description Rationale: Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke. Importantly, the risk of recurrence is highest immediately after the index event while antiplatelets cause bleeding. Aims and/or hypothesis: The ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial is testing whether short-term intensive antiplatelet therapy is safe and effective in reducing the early risk of recurrence as compared with standard guideline-based therapy. Design: TARDIS is an international multi-center prospective randomized open-label blinded–end-point trial, with funding from the UK Health Technology Assessment program. Patients with acute ischemic stroke or transient ischemic attack are randomized within 48 h to intensive/triple antiplatelet therapy or guideline antiplatelets taken for one-month. Patients or relatives give written informed (proxy) consent and all sites have research ethics approval. Analyses will be done by intention-to-treat. Study Outcome: The primary outcome is shift in stroke recurrent events and their severity, assessed using the modified Rankin Scale, at three-months. Discussion: This paper and attachment describe the trial’s statistical analysis plan, as developed from the protocol during recruitment and prior to unblinding of data. The statistical analysis plan contains design and methods for analyses, and unpopulated tables and figures for the primary and baseline publications. The data from the trial will provide the first large-scale randomized evidence for the use of intensive antiplatelet therapy for preventing recurrence after acute stroke and transient ischemic attack.
first_indexed 2025-11-14T19:27:26Z
format Article
id nottingham-35717
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:27:26Z
publishDate 2015
publisher SAGE Publications
recordtype eprints
repository_type Digital Repository
spelling nottingham-357172020-05-04T17:07:08Z https://eprints.nottingham.ac.uk/35717/ Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial Bath, Philip M.W. Robson, Katie Woodhouse, Lisa J. Sprigg, Nikola Dineen, Robert A. Pocock, Stuart J. Rationale: Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke. Importantly, the risk of recurrence is highest immediately after the index event while antiplatelets cause bleeding. Aims and/or hypothesis: The ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial is testing whether short-term intensive antiplatelet therapy is safe and effective in reducing the early risk of recurrence as compared with standard guideline-based therapy. Design: TARDIS is an international multi-center prospective randomized open-label blinded–end-point trial, with funding from the UK Health Technology Assessment program. Patients with acute ischemic stroke or transient ischemic attack are randomized within 48 h to intensive/triple antiplatelet therapy or guideline antiplatelets taken for one-month. Patients or relatives give written informed (proxy) consent and all sites have research ethics approval. Analyses will be done by intention-to-treat. Study Outcome: The primary outcome is shift in stroke recurrent events and their severity, assessed using the modified Rankin Scale, at three-months. Discussion: This paper and attachment describe the trial’s statistical analysis plan, as developed from the protocol during recruitment and prior to unblinding of data. The statistical analysis plan contains design and methods for analyses, and unpopulated tables and figures for the primary and baseline publications. The data from the trial will provide the first large-scale randomized evidence for the use of intensive antiplatelet therapy for preventing recurrence after acute stroke and transient ischemic attack. SAGE Publications 2015-04-02 Article PeerReviewed Bath, Philip M.W., Robson, Katie, Woodhouse, Lisa J., Sprigg, Nikola, Dineen, Robert A. and Pocock, Stuart J. (2015) Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial. International Journal of Stroke, 10 (3). pp. 449-451. ISSN 1747-4949 http://onlinelibrary.wiley.com/doi/10.1111/ijs.12445/abstract doi:10.1111/ijs.12445 doi:10.1111/ijs.12445
spellingShingle Bath, Philip M.W.
Robson, Katie
Woodhouse, Lisa J.
Sprigg, Nikola
Dineen, Robert A.
Pocock, Stuart J.
Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title_full Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title_fullStr Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title_full_unstemmed Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title_short Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
title_sort statistical analysis plan for the ‘triple antiplatelets for reducing dependency after ischaemic stroke’ (tardis) trial
url https://eprints.nottingham.ac.uk/35717/
https://eprints.nottingham.ac.uk/35717/
https://eprints.nottingham.ac.uk/35717/